{
    "Trade/Device Name(s)": [
        "Dexcom G6 Continuous Glucose Monitoring System"
    ],
    "Submitter Information": "Dexcom, Inc.",
    "510(k) Number": "K183206",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QBJ"
    ],
    "Summary Letter Date": "February 14, 2019",
    "Summary Letter Received Date": "November 19, 2018",
    "Submission Date": "November 16, 2018",
    "Regulation Number(s)": [
        "21 CFR 862.1355"
    ],
    "Regulation Name(s)": [
        "Integrated continuous glucose monitoring system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Dexcom G6 sensor",
        "Bluetooth Low Energy transmitter",
        "BLE enabled receiver",
        "Mobile app"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric measurement",
        "Glucose oxidase chemical reaction"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Transmitter",
        "Sensor",
        "Receiver",
        "App"
    ],
    "Document Summary": "FDA 510(k) summary for Dexcom G6 Continuous Glucose Monitoring System with updated transmitter design for real-time diabetes management",
    "Indications for Use Summary": "Indicated for real-time management of diabetes in persons age 2 years and older, replacing fingerstick blood glucose testing for treatment decisions, aiding detection of hyper- and hypoglycemia, and intended to autonomously communicate with digitally connected devices including automated insulin dosing systems",
    "fda_folder": "Clinical Chemistry"
}